T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence
T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence
Final stage II results of the CLL11 trial
Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease
Effective treatment of chemotherapy-refractory diffuse large B cell lymphoma
Oncology organisations in India and bone health in prostate and breast cancer
Integration of oncology and palliative care
Plurality of cancer
Growing rate of cancer incidence in India
Quality of life after robotic surgery treatment for prostate cancer
Translating guidelines from the West to the Indian sub-continent
Patient information needs in biomarkers and biobanking
Cancer cells and the immune system: a natural story?